Published by Josh White on 12th September 2023
(Sharecast News) - Hutchmed China reported significant strides in oncology research on Tuesday, completing patient enrollment for a bridging study of tazemetostat, and announcing pivotal results for the phase 3b clinical trial of savolitinib.
URL: http://www.digitallook.com/dl/news/story/33762759/...